Biologic TNFα inhibitors are a mainstay treatment option for patients with rheumatoid arthritis (RA) refractory to other treatment options. However, many patients either do not respond or relapse after initially responding to these agents. This study was carried out to identify biomarkers that can distinguish responder from non-responder patients before the initiation of treatment. The level of cytokines in plasma and those produced by ex vivo T cells, B cells and monocytes in 97 RA patients treated with biologic TNFα inhibitors was measured before treatment and after 1 and 3 months of treatment by multiplex analyses. The frequency of T cell subsets and intracellular cytokines were determined by flow cytometry. The results reveal that pre-t...
Introduction: Rheumatoid arthritis (RA) is a chronic inflammatory disease, characterized by synovial...
Rheumatoid arthritis (RA) is an autoimmune disorder characterized by chronic joint inflammation and ...
Objectives: Granulocyte monocyte colony-stimulating factor (GM-CSF) is currently considered a crucia...
Biologic TNFα inhibitors are a mainstay treatment option for patients with rheumatoid arthritis (RA)...
OBJECTIVES: To establish if changes in Th1/Th17 cell populations previously reported in experimental...
INTRODUCTION: Tumor necrosis factor inhibitor (TNFi) therapy is effective for rheumatoid arthritis (...
Data on the impact of biological therapies on the T-cell phenotype in rheumatoid arthritis are limit...
International audienceINTRODUCTION: Tumor necrosis factor inhibitor (TNFi) therapy is effective for ...
Background The goal of this study is to use comprehensive molecular profiling to cha...
Objectives: To establish if changes in Th1/Th17 cell populations previously reported in experimental...
Data on the impact of biological therapies on the T-cell phenotype in rheumatoid arthritis are limit...
To access publisher's full text version of this article click on the hyperlink belowRheumatoid arthr...
Objective: To investigate whether rheumatoid factor isotypes and anti-cyclic citrullinated peptide (...
Objective: To investigate whether rheumatoid factor isotypes and anti-cyclic citrullinated peptide (...
Aim: The laboratory findings are non-specific in Rheumatoid arthritis (RA). We have based our study ...
Introduction: Rheumatoid arthritis (RA) is a chronic inflammatory disease, characterized by synovial...
Rheumatoid arthritis (RA) is an autoimmune disorder characterized by chronic joint inflammation and ...
Objectives: Granulocyte monocyte colony-stimulating factor (GM-CSF) is currently considered a crucia...
Biologic TNFα inhibitors are a mainstay treatment option for patients with rheumatoid arthritis (RA)...
OBJECTIVES: To establish if changes in Th1/Th17 cell populations previously reported in experimental...
INTRODUCTION: Tumor necrosis factor inhibitor (TNFi) therapy is effective for rheumatoid arthritis (...
Data on the impact of biological therapies on the T-cell phenotype in rheumatoid arthritis are limit...
International audienceINTRODUCTION: Tumor necrosis factor inhibitor (TNFi) therapy is effective for ...
Background The goal of this study is to use comprehensive molecular profiling to cha...
Objectives: To establish if changes in Th1/Th17 cell populations previously reported in experimental...
Data on the impact of biological therapies on the T-cell phenotype in rheumatoid arthritis are limit...
To access publisher's full text version of this article click on the hyperlink belowRheumatoid arthr...
Objective: To investigate whether rheumatoid factor isotypes and anti-cyclic citrullinated peptide (...
Objective: To investigate whether rheumatoid factor isotypes and anti-cyclic citrullinated peptide (...
Aim: The laboratory findings are non-specific in Rheumatoid arthritis (RA). We have based our study ...
Introduction: Rheumatoid arthritis (RA) is a chronic inflammatory disease, characterized by synovial...
Rheumatoid arthritis (RA) is an autoimmune disorder characterized by chronic joint inflammation and ...
Objectives: Granulocyte monocyte colony-stimulating factor (GM-CSF) is currently considered a crucia...